Thomson Medical 1H FY2026 revenue up 7% to S$213m as multi‑year transformation narrows net loss to S$9.1m
Summary:
-
Group revenue rose 7.0% year on year to S$213.1m for 1H FY2026, driven by higher revenue intensity in Singapore, tighter pricing (fewer corporate discounts) and initial contributions from the new oncology centre in Malaysia.
-
Net loss after tax narrowed to S$9.1m from S$12.6m despite continued investments in specialist services, clinical talent and digital initiatives across the Group’s markets.
-
Management highlighted stronger patient volumes in Vietnam, though reported revenue was partially offset by negative foreign‑exchange movements in the Vietnamese dong.
-
CEO Dr Melvin Heng said the results show core operating businesses “responding well” to past investments, with growth coming from deeper multidisciplinary care in Singapore, oncology in Malaysia and rising volumes in Vietnam.
-
The Group will prioritise further revenue growth and operating leverage by expanding multidisciplinary offerings in Singapore, scaling oncology and specialist services in Malaysia and deepening access and affordability in Vietnam, while maintaining disciplined capital allocation.